Intratympanic corticosteroids in serous otitis

Investigating the effectiveness of intratympanic corticosteroid treatment in comparison with standard treatment on hearing condition in adults with serous otitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240108060650N1

Enrollment

Registered

2024-01-28

Start date

2023-10-23

Completion date

Unknown

Last updated

2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Serous otitis. Acute serous otitis media

Interventions

Intervention 1: Intervention group: In addition to receiving the same standard treatment as the control group, the study group receives intratympanic corticosteroid injection (methylprednisolone 50 mg

Eligibility

Sex/Gender

All

Age

12 Years to No maximum

Inclusion criteria

Inclusion criteria: Unilateral or bilateral serous otitis Gap between 10-30 in PTA Type B tympanometry Failure to improve within a month of the onset of symptoms

Exclusion criteria

Exclusion criteria: Reluctance to participate in a clinical study Nasopharyngeal carcinoma Systemic corticosteroids use

Design outcomes

Primary

Measure	Time frame
Gap in audiometry. Timepoint: One month and three month after treatment. Method of measurement: Audiometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKeyarmin Ghavam

Shahid Beheshti University of Medical Sciences

kagh7495@gmail.com+98 21 2213 4625

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026